期刊
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
卷 51, 期 3, 页码 407-410出版社
MOSBY, INC
DOI: 10.1016/j.jaad.2004.01.044
关键词
-
类别
Topical treatment of cutaneous lupus erythematosus usually includes potent glucocorticosteroids. However, prolonged use causes adverse side effects including skin atrophy as the foremost concern. In contrast to glucocorticosteroids, the anti-inflammatory and immunosuppressive macrolactam pimecrolimus has no atrophogenic potential. Affected areas of 11 patients with different forms of lupus erythematosus were treated with pimecrolimus 1% cream tinder semiocclusive conditions twice daily for 3 weeks. Skin involvement before and after therapy was assessed by means of a clinical score. in all patients, significant regression of skin lesions was observed after therapy (P<.001). This was an open and uncontrolled study on a limited number of cases. We suggest that pimecrolimus 1% cream Could be an efficacious and safe treatment option for cutaneous lupus erythematosus.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据